CG Oncology, Inc. (CGON)
CG Oncology, Inc. (CGON) from its SEC filings: 2025 revenue $4.0 million (+255% vs the year before), net margin -3985%, free cash flow -$132.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $4.0 million |
| Revenue growth | +255% |
| Net income | -$161.0 million |
| Net margin | -3985.1% |
| Free cash flow | -$132.5 million |
| Diluted EPS | $-2.08 |
| Cash | $19.6 million |
| Long-term debt | $3.0 million |
| Share count, 1 year | +16% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.